215 biotech leaders sign letter promising to price drugs ‘reasonably’

A group of biotech CEOs and other drug industry leaders signed a letter published Jan. 8 in STAT promising to price drugs “reasonably” and to improve drug access. 

Advertisement

The letter, which the leaders called a “New Commitment to Patients,” lists bullet points of “core principles and actions” the leaders promise to follow to ensure access to drugs and to price them responsibly. 

“We acknowledge that we have a moral obligation to develop the best medicines and ensure that every person who may benefit has access to them,” the leaders wrote. 

The leaders promised that the prices of their companies’ drugs will “reflect innovation and value to patients” and that “any price increases on our medicines must be reasonable and guided by the need for uninterrupted patient access.” 

They also promised to collaborate with policymakers, pharmacy benefit managers, payers and providers to work toward eliminating copays and deductibles for all patients.  

Read the full letter here

More articles on pharmacy:
Walgreens secures enterprisewide specialty accreditation
Drug price hike update: Merck, Allergen, Novartis raise prices
Regeneron restructures, cuts at least 15 jobs

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, Colibri Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.